BEUDAMED
    FDA Adverse Event Injury Summary report: N

    TRILOGY ACETABULAR LONGEVITY LINER

    MDR report key: 2212628 · Received August 11, 2011

    Report

    Report Number
    1822565-2011-01859
    Event Type
    Injury
    Date Received
    August 11, 2011
    Report Date
    July 15, 2011
    Manufacturer
    ZIMMER, INC.
    Product Code
    LPH
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    JA
    Reporter Occupation
    PHYSICIAN

    Narratives

    Additional Manufacturer Narrative · 1

    INFO WAS RECEIVED FROM A FOREIGN SOURCE WHO IS NOT REQUIRED TO COMPLETE FORM 3500A. EVAL SUMMARY: DEVICE WAS IN VIVO FOR APPROX 8 YRS AND 5 MONTHS AT THE TIME THAT THE EVENT WAS REPORTED. DEVICE WAS NOT AVAILABLE BECAUSE IT MAY REMAIN IMPLANTED; THEREFORE, CONDITION IS UNK. X-RAYS WERE NOT PROVIDED; IT IS UNK WHETHER THE COMPONENT WAS IMPLANTED WITH THE CORRECT FIT AND ORIENTATION AS PER THE SURGICAL TECHNIQUE. PT FACTORS THAT MAY AFFECT THE PERFORMANCE OF THE COMPONENTS SUCH AS ACTIVITY LEVEL, TYPE OF ACTIVITY (LOW IMPACT VS HIGH IMPACT), AND RELEVANT MEDICAL HISTORY ARE UNK. A DEFINITIVE ROOT CAUSE CANNOT BE DETERMINED WITH THE INFO PROVIDED. EVAL: REVIEW OF THE DEVICE HISTORY RECORDS DID NOT FIND ANY DEVIATIONS OR ANOMALIES. IT IS NOT SUSPECTED THAT THE PRODUCT FAILED TO MEET SPECS. THE INVESTIGATION COULD NOT VERIFY OR IDENTIFY ANY EVIDENCE OF PRODUCT CONTRIBUTION TO THE REPORTED PROBLEM. BASED ON THE INVESTIGATION, THE NEED FOR CORRECTIVE ACTION IS NOT INDICATED. SHOULD ADD'L SUBSTANTIVE INFO BE RECEIVED, THE COMPLAINT WILL BE REOPENED. ZIMMER, INC CONSIDERS THE INVESTIGATION CLOSED.

    Description of Event or Problem · 1

    IT IS REPORTED THAT OSTEOLYSIS HAS BEEN OBSERVED IN STEM ZONES 1 AND 7 BY GRUEN CLASSIFICATION AND CUP ZONES 2 AND 4 BY DELEE AND CHARNLEY CLASSIFICATION.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1 TRILOGY ACETABULAR LONGEVITY LINER LPH ZIMMER, INC. 67178800

    Patients

    Seq Age Sex Outcome Treatment
    1 59 YR Other